---
cover_image: >-
  https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=630&imgixProfile=propublicaAssets&q=90&w=1200&s=91e4137e84071d14a021a6c5b48bb2ca
date: '2025-02-14T15:37:10.000Z'
dateFolder: 2025/02/14
description: >-
  Taxpayers and charities helped develop Zolgensma. Then it debuted at a record
  price, ushering in a new class of wildly expensive drugs. Its story upends the
  widely held conception that high prices reflect huge industry investments in
  innovation.
isBasedOn: >-
  https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis
link: >-
  https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis
slug: >-
  2025-02-14-httpswwwpropublicaorgarticlezolgensma-sma-novartis-drug-prices-gene-therapy-avexis
tags:
  - health
  - healthcare
title: What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
---
Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.
